1-3 of 3
Katelyn Gauger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah
Journal: Blood
Blood (2024) 144 (Supplement 1): 4258.
https://doi.org/10.1182/blood-2024-201559
Published: 2024
Journal Articles

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah
Journal: Blood
Blood (2022) 140 (Supplement 1): 157–158.
https://doi.org/10.1182/blood-2022-157827
Published: 2022
Journal Articles

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)

Binod Dhakal, MBBS, Anita D'Souza, MBBS, Mehdi Hamadani, MD, Carlos E. Arce-Lara, MD, Katrina Schroeder, Saurabh Chhabra, MD, Nirav N Shah, MD, Katelyn Gauger, Taylor Keaton, Marcelo C. Pasquini, MD, Parameswaran Hari, MBBS, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1998.
https://doi.org/10.1182/blood-2018-99-110832
Published: 2018